Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus Update of the evidence-based guideline of the German Diabetes Association

被引：67

作者：

Matthaei, S. ^{[1
]}

Bierwirth, R.

Fritsche, A. ^{[2
]}

Gallwitz, B. ^{[2
]}

Haering, H. -U. ^{[2
]}

Joost, H. -G. ^{[3
]}

Kellerer, M. ^{[4
]}

Kloos, Ch. ^{[5
]}

Kunt, T.

Nauck, M. ^{[6
]}

Schernthaner, G. ^{[7
]}

Siegel, E. ^{[8
]}

Thienel, F. ^{[1
]}

机构：

[1] Diabet Zentrum Quakenbruck, Quakenbruck, Germany

[2] Univ Tubingen, Med Klin 4, Tubingen, Germany

[3] Deutsch Inst Ernahrungsforsch, Bergholz Rehbrucke, Germany

[4] Marienhosp Stuttgart, Zentrum Innere Med Diabetol & Endokrinol 1, Stuttgart, Germany

[5] Univ Jena, Klin Innere Med 3, Jena, Germany

[6] Diabet Zentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany

[7] Krankenhaus Rudolfstiftung, Med Abt 1, Vienna, Austria

[8] St Vincentius Kliniken 1, Karlsruhe, Germany

来源：

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES | 2009年 / 117卷 / 09期

关键词：

DIPEPTIDYL PEPTIDASE-4 INHIBITOR; METFORMIN-TREATED PATIENTS; IMPROVES GLYCEMIC CONTROL; SULFONYLUREA PLUS METFORMIN; CARDIOVASCULAR RISK-FACTORS; ACUTE MYOCARDIAL-INFARCTION; DRUG-NAIVE PATIENTS; TO-TARGET TRIAL; PLASMINOGEN-ACTIVATOR INHIBITOR; INSULIN COMBINATION THERAPY;

D O I：

10.1055/s-0029-1239559

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：522 / 557

页数：36

共 286 条

[61]

Dunning B E, 1997, Expert Opin Investig Drugs, V6, P1041, DOI 10.1517/13543784.6.8.1041

[62] Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes [J].

Ebeling, P ;

Teppo, AM ;

Koistinen, HA ;

Koivisto, VA .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2001, 50 (03) :283-287

[63] Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes melitus: A randomized, placebo-controlled study [J].

Einhorn, D ;

Rendell, M ;

Rosenzweig, J ;

Egan, JW ;

Mathisen, AL ;

Schneider, RL .

CLINICAL THERAPEUTICS, 2000, 22 (12) :1395-1409

[64] Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins -: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus [J].

Emanuele, N ;

Azad, N ;

Abraira, C ;

Henderson, W ;

Colwell, J ;

Levin, S ;

Nuttall, F ;

Comstock, J ;

Sawin, C ;

Silbert, C ;

Marcovina, S ;

Lee, HS .

ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (22) :2485-2490

[65] Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome [J].

Esposito, K ;

Ciotola, M ;

Carleo, D ;

Schisano, B ;

Saccomanno, F ;

Sasso, FC ;

Cozzolino, D ;

Assaloni, R ;

Merante, D ;

Ceriello, A ;

Giugliano, D .

DIABETES CARE, 2006, 29 (05) :1071-1076

[66] Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review [J].

Eurich, Dean T. ;

McAlister, Finlay A. ;

Blackburn, David F. ;

Majumdar, Sumit R. ;

Tsuyuki, Ross T. ;

Varney, Janice ;

Johnson, Jeffrey A. .

BMJ-BRITISH MEDICAL JOURNAL, 2007, 335 (7618) :497-501

[67] Metformin and reduced risk of cancer in diabetic patients [J].

Evans, JMM ;

Donnelly, LA ;

Emslie-Smith, AM ;

Alessi, DR ;

Morris, AD .

BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7503) :1304-1305

[68] Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin [J].

Evans, JMM ;

Ogston, SA ;

Emslie-Smith, A ;

Morris, AD .

DIABETOLOGIA, 2006, 49 (05) :930-936

[69]

*FACHINFO ACT, 2000, BUND PHARM IND ZUS M, P1

[70] Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes [J].

Fineman, MS ;

Shen, LZ ;

Taylor, K ;

Kim, DD ;

Baron, AD .

DIABETES-METABOLISM RESEARCH AND REVIEWS, 2004, 20 (05) :411-417

← 2 3 4 5 6 7 8 9 10 11 →